APO Research
Talk to an analyst

APO RESEARCH · REPORT

Chemotherapy Induced Peripheral Neuropathy Treatment

CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemotherapy has ended.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemotherapy has ended.

There are no approved therapies to combat the debilitating symptoms of CIPN now. Current alternatives include Palliative care using antidepressants, antiepileptic drugs, or opioids, all of which have well known adverse side effects.

Selected research

Market Structure

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025190 pages

Choose your research edition.

Industry ResearchChemotherapy Induced Peripheral Neuropathy Treatment Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Chemotherapy Induced Peripheral Neuropathy Treatment Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Chemotherapy Induced Peripheral Neuropathy Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Chemotherapy Induced Peripheral Neuropathy Treatment Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Chemotherapy Induced Peripheral Neuropathy Treatment Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemotherapy has ended.

There are no approved therapies to combat the debilitating symptoms of CIPN now. Current alternatives include Palliative care using antidepressants, antiepileptic drugs, or opioids, all of which have well known adverse side effects.

Americas is the largest market with about 47% market share. Europe is follower, accounting for about 27% market share.

Read the full market overview

The key players are Aptinyx Inc, Asahi Kasei Pharma Corp, Regenacy Pharmaceuticals, MAKScientific LLC, Metys Pharmaceuticals AG, Nemus Bioscience Inc, PledPharma, Sova Pharmaceuticals Inc, DermaXon LLC, Kineta Inc, Krenitsky Pharmaceuticals Inc, PeriphaGen, Apexian Pharma, WinSanTor etc.

This report provides an overview of the global Chemotherapy Induced Peripheral Neuropathy Treatment market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Chemotherapy Induced Peripheral Neuropathy Treatment and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Chemotherapy Induced Peripheral Neuropathy Treatment sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Chemotherapy Induced Peripheral Neuropathy Treatment market size, projected growth trends, production technologies, key applications, and end-use industries.

Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Company

Aptinyx Inc

Asahi Kasei Pharma Corp

Regenacy Pharmaceuticals

MAKScientific LLC

Metys Pharmaceuticals AG

Nemus Bioscience Inc

PledPharma

Sova Pharmaceuticals Inc

DermaXon LLC

Kineta Inc

Krenitsky Pharmaceuticals Inc

PeriphaGen

Apexian Pharma

WinSanTor

Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Type

Calcium Channel α2-delta Ligands

Antidepressants

Opioids

Others

Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Application

Platinum Agents

Taxanes

Vinca Alkaloids

Others

Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chemotherapy Induced Peripheral Neuropathy Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Chemotherapy Induced Peripheral Neuropathy Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chemotherapy Induced Peripheral Neuropathy Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Chemotherapy Induced Peripheral Neuropathy Treatment market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Chemotherapy Induced Peripheral Neuropathy Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Chemotherapy Induced Peripheral Neuropathy Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Chemotherapy Induced Peripheral Neuropathy Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Chemotherapy Induced Peripheral Neuropathy Treatment Industry Trends Table 2. Chemotherapy Induced Peripheral Neuropathy Treatment Industry Drivers Table 3. Chemotherapy Induced Peripheral Neuropathy Treatment Industry Opportunities and Challenges Table 4. Chemotherapy Induced Peripheral Neuropathy Treatment Industry Restraints Table 5. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Manufacturers Table 9. Global Chemotherapy Induced Peripheral Neuropathy Treatment Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Chemotherapy Induced Peripheral Neuropathy Treatment Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Chemotherapy Induced Peripheral Neuropathy Treatment Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturers, Product Type & Application Table 13. Global Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Chemotherapy Induced Peripheral Neuropathy Treatment by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Calcium Channel α2-delta Ligands Table 17. Major Manufacturers of Antidepressants Table 18. Major Manufacturers of Opioids Table 19. Major Manufacturers of Others Table 20. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2021-2026) & (K Units) Table 22. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2027-2032) & (K Units) Table 23. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2021-2026) Table 24. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2027-2032) Table 25. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 26. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2021-2026) & (K Units) Table 27. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2027-2032) & (K Units) Table 28. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Type (2021-2026) Table 29. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Platinum Agents Table 31. Major Manufacturers of Taxanes Table 32. Major Manufacturers of Vinca Alkaloids Table 33. Major Manufacturers of Others Table 34. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2021-2026) & (K Units) Table 36. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2027-2032) & (K Units) Table 37. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2021-2026) Table 38. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2027-2032) Table 39. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2021-2026) & (K Units) Table 41. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2027-2032) & (K Units) Table 42. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application (2021-2026) Table 43. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application (2027-2032) Table 44. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2021-2026) & (K Units) Table 46. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region (2021-2026) Table 47. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2021-2026) & (K Units) Table 51. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2027-2032) & (K Units) Table 52. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2021-2026) & (K Units) Table 54. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2027-2032) & (K Units) Table 61. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region (2021-2026) Table 65. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region (2027-2032) Table 66. Aptinyx Inc Company Information Table 67. Aptinyx Inc Business Overview Table 68. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 70. Aptinyx Inc Recent Development Table 71. Asahi Kasei Pharma Corp Company Information Table 72. Asahi Kasei Pharma Corp Business Overview Table 73. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 75. Asahi Kasei Pharma Corp Recent Development Table 76. Regenacy Pharmaceuticals Company Information Table 77. Regenacy Pharmaceuticals Business Overview Table 78. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 80. Regenacy Pharmaceuticals Recent Development Table 81. MAKScientific LLC Company Information Table 82. MAKScientific LLC Business Overview Table 83. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 85. MAKScientific LLC Recent Development Table 86. Metys Pharmaceuticals AG Company Information Table 87. Metys Pharmaceuticals AG Business Overview Table 88. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 90. Metys Pharmaceuticals AG Recent Development Table 91. Nemus Bioscience Inc Company Information Table 92. Nemus Bioscience Inc Business Overview Table 93. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 95. Nemus Bioscience Inc Recent Development Table 96. PledPharma Company Information Table 97. PledPharma Business Overview Table 98. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 100. PledPharma Recent Development Table 101. Sova Pharmaceuticals Inc Company Information Table 102. Sova Pharmaceuticals Inc Business Overview Table 103. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 105. Sova Pharmaceuticals Inc Recent Development Table 106. DermaXon LLC Company Information Table 107. DermaXon LLC Business Overview Table 108. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 110. DermaXon LLC Recent Development Table 111. Kineta Inc Company Information Table 112. Kineta Inc Business Overview Table 113. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 115. Kineta Inc Recent Development Table 116. Krenitsky Pharmaceuticals Inc Company Information Table 117. Krenitsky Pharmaceuticals Inc Business Overview Table 118. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 120. Krenitsky Pharmaceuticals Inc Recent Development Table 121. PeriphaGen Company Information Table 122. PeriphaGen Business Overview Table 123. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 125. PeriphaGen Recent Development Table 126. Apexian Pharma Company Information Table 127. Apexian Pharma Business Overview Table 128. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 130. Apexian Pharma Recent Development Table 131. WinSanTor Company Information Table 132. WinSanTor Business Overview Table 133. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 135. WinSanTor Recent Development Table 136. Key Raw Materials Table 137. Raw Materials Key Suppliers Table 138. Chemotherapy Induced Peripheral Neuropathy Treatment Distributors List Table 139. Chemotherapy Induced Peripheral Neuropathy Treatment Customers List Table 140. Research Programs/Design for This Report Table 141. Authors List of This Report Table 142. Secondary Sources Table 143. Primary Sources List of Figures Figure 1. Chemotherapy Induced Peripheral Neuropathy Treatment Product Image Figure 2. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (2021-2032) & (K Units) Figure 5. Global Chemotherapy Induced Peripheral Neuropathy Treatment Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Chemotherapy Induced Peripheral Neuropathy Treatment Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Calcium Channel α2-delta Ligands Image Figure 9. Antidepressants Image Figure 10. Opioids Image Figure 11. Others Image Figure 12. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2021-2032) Figure 15. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Type (2021-2032) Figure 18. Platinum Agents Image Figure 19. Taxanes Image Figure 20. Vinca Alkaloids Image Figure 21. Others Image Figure 22. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2021-2032) Figure 25. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application (2021-2032) Figure 28. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country (2021-2032) Figure 30. U.S. Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country (2021-2032) Figure 35. Germany Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country (2021-2032) Figure 42. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country (2021-2032) Figure 50. Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2021-2032) & (US$ Million) Figure 61. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2021-2032) & (US$ Million) Figure 63. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Chemotherapy Induced Peripheral Neuropathy Treatment Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Chemotherapy Induced Peripheral Neuropathy Treatment Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Calcium Channel α2-delta Ligands
  • Antidepressants
  • Opioids
  • Others
Applications
  • Platinum Agents
  • Taxanes
  • Vinca Alkaloids
  • Others
Companies covered
  • Aptinyx Inc
  • Asahi Kasei Pharma Corp
  • Regenacy Pharmaceuticals
  • MAKScientific LLC
  • Metys Pharmaceuticals AG
  • Nemus Bioscience Inc
  • PledPharma
  • Sova Pharmaceuticals Inc
  • DermaXon LLC
  • Kineta Inc
  • Krenitsky Pharmaceuticals Inc
  • PeriphaGen
  • Apexian Pharma
  • WinSanTor

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Dynamics
  1. 2.1 Chemotherapy Induced Peripheral Neuropathy Treatment Industry Trends
  2. 2.2 Chemotherapy Induced Peripheral Neuropathy Treatment Industry Drivers
  3. 2.3 Chemotherapy Induced Peripheral Neuropathy Treatment Industry Opportunities and Challenges
  4. 2.4 Chemotherapy Induced Peripheral Neuropathy Treatment Industry Restraints
3 Chemotherapy Induced Peripheral Neuropathy Treatment Market by Manufacturers
  1. 3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Manufacturers (2021-2026)
  3. 3.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Chemotherapy Induced Peripheral Neuropathy Treatment Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturers, Product Type & Application
  7. 3.7 Global Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Chemotherapy Induced Peripheral Neuropathy Treatment Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Chemotherapy Induced Peripheral Neuropathy Treatment Tier 1, Tier 2, and Tier 3
4 Chemotherapy Induced Peripheral Neuropathy Treatment Market by Type
  1. 4.1 Chemotherapy Induced Peripheral Neuropathy Treatment Type Introduction
  2. 4.1.1 Calcium Channel α2-delta Ligands
  3. 4.1.2 Antidepressants
  4. 4.1.3 Opioids
  5. 4.1.4 Others
  6. 4.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type
  7. 4.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2021-2032)
  9. 4.2.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2021-2032)
  10. 4.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type
  11. 4.3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2021-2032)
  13. 4.3.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Type (2021-2032)
5 Chemotherapy Induced Peripheral Neuropathy Treatment Market by Application
  1. 5.1 Chemotherapy Induced Peripheral Neuropathy Treatment Application Introduction
  2. 5.1.1 Platinum Agents
  3. 5.1.2 Taxanes
  4. 5.1.3 Vinca Alkaloids
  5. 5.1.4 Others
  6. 5.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application
  7. 5.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2021-2032)
  9. 5.2.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2021-2032)
  10. 5.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application
  11. 5.3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2021-2032)
  13. 5.3.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application (2021-2032)
6 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region
  1. 6.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2021-2032)
  3. 6.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2021-2026)
  4. 6.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region
  1. 7.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region
  2. 7.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region (2021-2026)
  4. 7.1.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region (2027-2032)
  5. 7.1.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2021-2032)
  8. 7.2.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2021-2032)
  11. 7.3.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Aptinyx Inc
  2. 8.1.1 Aptinyx Inc Company Information
  3. 8.1.2 Aptinyx Inc Business Overview
  4. 8.1.3 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  6. 8.1.5 Aptinyx Inc Recent Developments
  7. 8.2 Asahi Kasei Pharma Corp
  8. 8.2.1 Asahi Kasei Pharma Corp Company Information
  9. 8.2.2 Asahi Kasei Pharma Corp Business Overview
  10. 8.2.3 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  12. 8.2.5 Asahi Kasei Pharma Corp Recent Developments
  13. 8.3 Regenacy Pharmaceuticals
  14. 8.3.1 Regenacy Pharmaceuticals Company Information
  15. 8.3.2 Regenacy Pharmaceuticals Business Overview
  16. 8.3.3 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  18. 8.3.5 Regenacy Pharmaceuticals Recent Developments
  19. 8.4 MAKScientific LLC
  20. 8.4.1 MAKScientific LLC Company Information
  21. 8.4.2 MAKScientific LLC Business Overview
  22. 8.4.3 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  24. 8.4.5 MAKScientific LLC Recent Developments
  25. 8.5 Metys Pharmaceuticals AG
  26. 8.5.1 Metys Pharmaceuticals AG Company Information
  27. 8.5.2 Metys Pharmaceuticals AG Business Overview
  28. 8.5.3 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  30. 8.5.5 Metys Pharmaceuticals AG Recent Developments
  31. 8.6 Nemus Bioscience Inc
  32. 8.6.1 Nemus Bioscience Inc Company Information
  33. 8.6.2 Nemus Bioscience Inc Business Overview
  34. 8.6.3 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  36. 8.6.5 Nemus Bioscience Inc Recent Developments
  37. 8.7 PledPharma
  38. 8.7.1 PledPharma Company Information
  39. 8.7.2 PledPharma Business Overview
  40. 8.7.3 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  42. 8.7.5 PledPharma Recent Developments
  43. 8.8 Sova Pharmaceuticals Inc
  44. 8.8.1 Sova Pharmaceuticals Inc Company Information
  45. 8.8.2 Sova Pharmaceuticals Inc Business Overview
  46. 8.8.3 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  48. 8.8.5 Sova Pharmaceuticals Inc Recent Developments
  49. 8.9 DermaXon LLC
  50. 8.9.1 DermaXon LLC Company Information
  51. 8.9.2 DermaXon LLC Business Overview
  52. 8.9.3 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  54. 8.9.5 DermaXon LLC Recent Developments
  55. 8.10 Kineta Inc
  56. 8.10.1 Kineta Inc Company Information
  57. 8.10.2 Kineta Inc Business Overview
  58. 8.10.3 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  60. 8.10.5 Kineta Inc Recent Developments
  61. 8.11 Krenitsky Pharmaceuticals Inc
  62. 8.11.1 Krenitsky Pharmaceuticals Inc Company Information
  63. 8.11.2 Krenitsky Pharmaceuticals Inc Business Overview
  64. 8.11.3 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  66. 8.11.5 Krenitsky Pharmaceuticals Inc Recent Developments
  67. 8.12 PeriphaGen
  68. 8.12.1 PeriphaGen Company Information
  69. 8.12.2 PeriphaGen Business Overview
  70. 8.12.3 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  72. 8.12.5 PeriphaGen Recent Developments
  73. 8.13 Apexian Pharma
  74. 8.13.1 Apexian Pharma Company Information
  75. 8.13.2 Apexian Pharma Business Overview
  76. 8.13.3 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  78. 8.13.5 Apexian Pharma Recent Developments
  79. 8.14 WinSanTor
  80. 8.14.1 WinSanTor Company Information
  81. 8.14.2 WinSanTor Business Overview
  82. 8.14.3 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  84. 8.14.5 WinSanTor Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Chemotherapy Induced Peripheral Neuropathy Treatment Value Chain Analysis
  2. 9.1.1 Chemotherapy Induced Peripheral Neuropathy Treatment Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Chemotherapy Induced Peripheral Neuropathy Treatment Production Mode & Process
  6. 9.2 Chemotherapy Induced Peripheral Neuropathy Treatment Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Chemotherapy Induced Peripheral Neuropathy Treatment Distributors
  9. 9.2.3 Chemotherapy Induced Peripheral Neuropathy Treatment Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst